Skip to main content

Side-Effects Management

Lorazepam Treatment May Be Linked to Worse Outcomes for Pancreatic Cancer
Pancreatic Cancer, Side-Effects Management
November 2023 Vol 16, No 6
Philadelphia, PA—Patients with pancreatic cancer who took the benzodiazepine lorazepam (Ativan), commonly prescribed to treat anxiety during cancer treatment, had a shorter progression-free survival than patients who did not, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research. Read More ›
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
By Wayne Kuznar
Side-Effects Management
Web Exclusives
The NCCN’s first guideline for side effects from immunotherapy recognizes a new spectrum of events in patients who are receiving immune checkpoint inhibitor therapy. Read More ›
Suboptimal Dosing of Filgrastim Is Acceptable for Treatment of Chemotherapy-Induced Neutropenia
Suboptimal Dosing of Filgrastim Is Acceptable for Treatment of Chemotherapy-Induced Neutropenia
By Audrey Andrews
Side-Effects Management
TOP - August 2018, Vol 11, No 2

Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.

Read More ›
Understanding Immunotherapy Late Adverse Effects in Cancer Survivors
Understanding Immunotherapy Late Adverse Effects in Cancer Survivors
By Meg Barbor, MPH
Side-Effects Management, Side-Effects Management
TOP - May 2018, Vol 11, No 1

At the 2018 Cancer Survivorship Symposium, Katy K. Tsai, MD, suggested that cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint because of its novel mechanisms of action, extended treatment periods, and unique toxicities.

Read More ›
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Breast Cancer, Side-Effects Management, Side-Effects Management
TOP - May 2018, Vol 11, No 1

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

Read More ›
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
By Phoebe Starr
Side-Effects Management, Side-Effects Management
TOP - May 2017, Vol 10, No 2
Real-world experience at the University of Texas M.D. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis. Read More ›
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
By Phoebe Starr
Side-Effects Management, Side-Effects Management
TOP - May 2017, Vol 10, No 2
The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. Read More ›